Live Event
Measuring Antigen-specific Immune Responses at the Single-cell Level
March 04, 2026 - March 05, 2026
Learn how single-cell immune monitoring strategies can be used to measure antigen-specific responses with confidence, from early discovery through to clinical trials.
In this webinar, you will learn:
How to assess whether FluoroSpot is an appropriate immune monitoring assay for your research or development goals
Key factors that influence FluoroSpot performance, including sensitivity, multiplexing, and practical implementation considerations
How optical setup, plate choice, and background control impact data quality and reproducibility
Practical insights from applying FluoroSpot in a real-world development program
Understanding antigen-specific immune responses is central to many areas of biomedical research, including infectious disease, vaccine development, and immunotherapy.
To support experimental and translational decisions, you need tools that resolve functional immune responses at the single-cell level. Plus, your assay must remain sensitive and reproducible from early discovery and preclinical development through to clinical trials.
FluoroSpot has become a widely used immune monitoring assay for this purpose, enabling multiplexed detection of secreted immune mediators, including cytokines, from antigen-responsive cells.
However, generating reliable and interpretable FluoroSpot data depends on assay design, appropriate optical setup, and a clear understanding of the assay’s strengths and limitations.
In this three-part webinar, you'll learn how this single-cell immune response assay, FluoroSpot, can be effectively used across discovery research, preclinical development, and clinical trials.
The session will begin with an overview of key use cases in immune research and clinical development, using cancer immunotherapy as a practical example to uncover assay sensitivity, multiplexing capabilities, and practical considerations that influence assay selection.
We'll then focus on optical performance, exploring how plate choice and background control directly affect data quality and reproducibility.
The webinar concludes with a real-world case study from a cancer immunotherapy program, sharing lessons learned from implementing FluoroSpot and highlighting considerations that translate from preclinical optimization into clinical use.
James Perry,
James began his career at Beth Israel Deaconess Medical Center and Harvard University, where he developed assays for the HIV Vaccine Trials Network's global initiatives. He then moved on to support discovery and translational work at Genocea Biosciences, focusing on personalized cancer vaccines. Currently, at Elicio Therapeutics, James leads clinical immunogenicity studies for a lymph node-targeted mKRAS cancer immunotherapy in pancreatic ductal adenocarcinoma.
Close
Jun Park,
Jun serves as the R&D Manager at MilliporeSigma. He studied Biomaterials and Immunology at the University of Toronto and completed his postdoctoral work at Harvard Medical School, where he investigated small molecule regulators of beta integrins. Since joining MilliporeSigma in 2006, Jun has primarily focused on developing novel detection technologies and cell-based assays.
Close
Renata Varnaite
Renata earned her PhD in Medical Science from Karolinska Institutet, Sweden, in 2022. During her research, she utilized FluoroSpot assays to measure human T-cell and B-cell responses to infections and vaccines. In 2023, she joined Mabtech, where she assists customers in effectively applying ELISpot/FluoroSpot technology across various therapeutic areas, ranging from infectious disease vaccines to cell and gene therapies.
CloseEvents
-
Measuring Antigen-specific Immune Responses at the Single-cell Level - March 04, 2026, 04:00 PM (London)
-
Measuring Antigen-specific Immune Responses at the Single-cell Level - March 05, 2026, 03:00 AM (London)
